A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was not conducted in the United States. Many people with type 2 diabetes also have high cholesterol levels. The purpose of this study was to evaluate the effects of vildagliptin, an unapproved drug, on blood lipid measures such as triglycerides and cholesterol in people with type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Blood glucose criteria must be met

• Genetic markers associated with increased risk of cardiovascular disease

• Not currently on drug therapy for type 2 diabetes

• Body mass index (BMI) in the range 25-40

Exclusion Criteria:

• Pregnancy or lactation

• Type 1 diabetes

• High cholesterol as defined by the protocol

• Evidence of serious diabetic complications

• Other protocol-defined exclusion criteria may apply